Free-text search
Articles per year:
Content Types
-
Gubra CEO steps down with immediate effect
Shortly after presenting a new 2030 strategy, Danish biotech company Gubra has replaced its CEO.
-
Gubra seeks to double number of candidates in 2030
Gubra is seeking to scale its business towards 2030 with the plans of expanding their clinical-stage pipeline.
-
A Biotech CTO on the Outsourcing Dilemma: “The Stakes Are Extremely High”
For small biotech companies, external expertise can be essential to moving drug development forward. But what happens when priorities shift, financing changes and every milestone matters? Ahead of Pharma Outsourcing – Find the Right Partner in Stockholm on 2 December, we spoke with conference moderator Pernille Hemmingsen, CTO at Adcendo, about the challenges of working with external development partners.
-
A Biotech CTO on the Outsourcing Dilemma: “The Stakes Are Extremely High”
For small biotech companies, external expertise can be essential to moving drug development forward. But what happens when priorities shift, financing changes and every milestone matters? Ahead of Pharma Outsourcing – Find the Right Partner in Stockholm on 2 December, we spoke with conference moderator Pernille Hemmingsen, CTO at Adcendo, about the challenges of working with external development partners.
-
Omnio raises €2.9m for chronic wound therapy
Swedish biotech company Omnio has secured €2.9 million from existing investors and shareholders. The funding will be used to advance its plasminogen-based biological therapy for chronic wounds into first-in-human clinical studies.
-
ResoTher eyes pharma deal as heart attack candidate moves forward
ResoTher Pharma is taking its lead candidate RTP-026 into a larger international study after seeing encouraging efficacy signals in patients with severe heart attacks. The Danish biotech hopes the next readout will bring it closer to a major pharma partnership.
-
Tataa is acquired by a Dutch firm
The Swedish laboratory company TATAA Biocenter is being acquired by the Dutch CRO Single Cell Discoveries.
-
Alzinova strengthens its cash position ahead of Phase II study
The Swedish research company Alzinova has initiated the start‑up phase of its Phase II study in Alzheimer’s disease – and is simultaneously announcing a rights issue of up to SEK 51 million to help finance the study.
-
Storaffär inom svensk kontraktsforskning – Pelago köper RG Discovery
Expertis inom biologi och kemi slås ihop under samma tak när Pelago Bioscience köper RG Discovery och skapar ett av de största svenska CRO-bolagen inom tidig läkemedelsutveckling.
-
Genovis i samarbetsavtal med nederländsk partner
Biotechbolaget Genovis har ingått ett partnerskap med nederländska Single Cell Discoveries för att möjliggöra storskaliga analyser av genuttryck.
-
Evotec kapar 800 jobb och stänger anläggningar
Tyska CRO-bolaget Evotec drar ned rejält. Upp till 800 tjänster försvinner och antalet anläggningar ska minska från 19 till 10 inom två år. Det motsvarar omkring en sjättedel av bolagets 4 800 anställda globalt.
-
Helena Lüning blir chef på Swetrial
Läkemedelsverket anställer CRO-profilen Helena Lüning som enhetschef för Swetrial, det nationella partnerskapet för kliniska prövningar.
-
Amerikansk CRO köper leverantör av försöksdjur
Charles River Laboratories köper en kambodjansk leverantör av primater för 510 miljoner dollar, motsvarande 4,7 miljarder kronor. Syftet är att säkra tillgången till försöksdjur för medicinsk forskning.
BREAKING